Use of genomic test does not increase active surveillance adoption in African-American men

The genomic assay did not increase use of active surveillance in a predominantly African-American population of men with favorable-risk prostate cancer.

Imaging Modalities for Evaluating Biochemical Recurrence in Prostate Cancer 

An expert panel reacts to polling data on choice of imaging modalities for patients with prostate patients after definitive therapy and share their insights about best practices.  

Combo of Novel BET inhibitor and enzalutamide advances in mCRPC pipeline

Exploration of the novel combination continues after early-phase published data showed promising clinical activity.